Genitourinary Radiology: Page 73

Medrad, GE release eCoil
By AuntMinnie.com staff writers
Medrad and GE Healthcare have introduced an endorectal coil for 3-tesla MR imaging.
August 1, 2006
IsoRay pulls Nasdaq application for now
By AuntMinnie.com staff writers
IsoRay has withdrawn its application for a listing on the Nasdaq stock exchange because the Richland, WA, company's stock did not meet the capital market's minimum bid requirement of $4 for more than 10 trading days.
July 6, 2006
IsoRay begins cesium-131 production testing
By AuntMinnie.com staff writers
Medical isotope developer IsoRay Medical said it has begun production testing the creation of cesium-131 at the Idaho National Laboratory in Idaho Falls.
July 6, 2006
Cook nets FDA nod
By AuntMinnie.com staff writers
Interventional technology firm Cook has received U.S. Food and Drug Administration clearance to market its Zilver vascular stent for use in treating symptomatic vascular disease of the iliac arteries.
July 5, 2006
IsoRay forecasts record seed orders
By AuntMinnie.com staff writers
Medical isotope developer IsoRay Medical said it is forecasting cesium-131 seed implant sales for the treatment of prostate cancer to improve by 100% for its fiscal 2006 fourth quarter (end-June 30).
June 19, 2006
MDCT edges MRI in characterizing kidney lesions
By Eric Barnes
MDCT did a little better than MRI in the task of characterizing kidney lesions in a new study by German researchers, but both modalities were only mediocre in differentiating benign from malignant lesions.
June 19, 2006
MDCT makes inroads in urology, biopsy guidance, and oncology imaging
By Wayne Forrest
With its progression from four- to 64-slice technology, MDCT is taking on increasingly prominent roles in a number of areas, including urography, oncology imaging, and biopsy guidance, according to presentations at last week's International Symposium on Multidetector-Row CT in San Francisco.
June 18, 2006
FDA issues gadolinium health advisory
By AuntMinnie.com staff writers
The U.S. Food and Drug Administration has issued a health advisory regarding MRI contrast agents containing gadolinium after two dozen cases of a rare disease that developed in European patients following administration of a gadolinium-based agent.
June 14, 2006
Assessing patient risk will help prevent contrast-induced nephropathy
By Wayne Forrest
SAN FRANCISCO - With the increasing use of contrast media, contrast-induced nephropathy (CIN) is becoming a more critical issue for radiologists, cardiologists, and nephrologists. At this week's International Symposium on Multidetector-Row CT, physicians debated the most appropriate steps to prevent CIN, which patients are most at-risk, and the efficacy of low- and iso-osmolar contrast media in reducing incidents of CIN.
June 14, 2006
MR technique, criteria hone in on prostate cancer progression
By Shalmali Pal
Two new studies take a closer look at the progression of prostate cancer with MRI. Researchers from Switzerland performed prostate MR spectroscopy (MRS) using 2D S-PRESS, while a group from Memorial Sloan Kettering Cancer Center in New York City used MRI to detect, localize, and stage transition zone prostate cancers.
June 13, 2006
Firm raises eyebrows with push to enforce anti-kidney-failure patent
By Wayne Forrest
A start-up company's efforts to enforce a patent it received for preventing kidney failure during contrast administration has a number of hospitals consulting with their attorneys. A central issue is whether patent holders can successfully enforce patents against physicians who are using generically available compounds and devices for treating patients.
June 12, 2006
GE investigates Omniscan cases
By AuntMinnie.com staff writers
GE Healthcare of Chalfont St. Giles, U.K., is investigating 25 cases of a rare kidney disease that developed in European patients after administration of the company's Omniscan MRI contrast agent.
June 11, 2006
Previous Page
Page 73 of 93
Next Page